New cell line could lead to more reliable vaccine development to fight costly pig virus
2 March 2021
Vaccine manufacturer could turn the tide on ASF
28 September 2020
by Katy Moore, Midwest Messenger
Aptimmune Biologics Adds CEO and Technical Consultant to Management Team
on January 14, 2019
with
No Comments
St. Louis, MO (January 8, 2019) – Aptimmune Biologics announces the addition of two members to the company’s management team to start the New Year. Heather Bessoff, DVM, has joined the company as chief executive officer. In her new … Read More
Aptimmune Biologics and Kemin Industries Announce Partnership
on August 7, 2018
with
No Comments
Kemin Industries acquires equity position in Aptimmune Biologics and creates Kemin Biologics to market Aptimmune’s Barricade™ technology in swine DES MOINES, IA/ST. LOUIS, MO (August 7, 2018) – Today Aptimmune Biologics and Kemin Industries officially announced their partnership in the … Read More
Aptimmune Completes $6 Million Series B Funding, Moves Headquarters & Lab to St. Louis
on January 23, 2018
with
No Comments
St. Louis, Mo. (January 22, 2018) – Aptimmune Biologics announces it has completed its Series B funding initiative, raising more than $6 million from several investors. This increases the combined total investment to almost $9 million, generated by the company … Read More
Aptimmune Biologics Receives Iowa Biotech Innovation Showcase’s Top Company Award
on April 3, 2017
with
No Comments
Swine-vaccine developer recognized as Top Company at this year’s Partnering for Growth Biotech Innovation Showcase & Forum CHAMPAIGN, Illinois (March 24, 2017) – Aptimmune Biologics was awarded this year’s Biotech Innovation Showcase’s Top Company Award at the 2017 Partnering for … Read More
Iowa State University and Aptimmune Join Forces to Improve PRRSV Isolation
on December 15, 2016
with
No Comments
CHAMPAIGN, Ill. (December 14, 2016) – The Iowa State University Veterinary Diagnostic Laboratory is teaming up with Aptimmune Biologics Inc. to develop innovative solutions to fight costly viral diseases of swine. The agreement enables Iowa State to use Aptimmune’s patented … Read More
Aptimmune Biologics Selected by The Yield Lab to Participate in Ag Technology Accelerator Program
on November 17, 2016
with
No Comments
Swine mucosal vaccine company received $100,000 in funding, plus networking, mentorship and other support CHAMPAIGN, Illinois (November 17, 2016) – Aptimmune Biologics was selected by The Yield Lab, a St. Louis-based agriculture technology business accelerator and investor, to participate in a … Read More
Aptimmune Uses Novel Technology to Fight Swine Pathogens
on October 10, 2016
with
No Comments
JAMIE JOHANSEN | AgWired | June 21, 2016 Just last year the small team raised their first round of funding and brought on CEO, Aaron Gilbertie, to help lead the company through the development, product registration and commercialization of Aptimmune’s … Read More
Aptimmune Offering New Vaccination Technology
on October 10, 2016
with
No Comments
SwineCast | July 12, 2016 Aptimmune Biologics is bringing new intra-nasal vaccination technology to the swine industry. CEO Aaron Gilbertie discusses the company’s focus and products at World Pork Expo. Read More…
Swine Vaccine Maker at Ag Innovations Showcase
on October 7, 2016
with
No Comments
JULIE HARKER | Brownfield Ag News | September 21, 2016 A wide variety of ag innovators is asking for support at the Ag Innovations Showcase. A startup company that provides crickets for poultry feed, a tropical weather forecast provider for … Read More
Aptimmune Biologics Raises $2.75 Million of Series A Funding Led by Arsenal Capital Management
on June 23, 2016
with
No Comments
Company will create new swine vaccines based on advanced mucosal technology New CEO joins the company to drive development and commercialization CHAMPAIGN, Illinois – July 7, 2015 – Aptimmune Biologics, a mucosal vaccine company developing novel swine vaccines for PRRSV … Read More